Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Bempikibart may help regrow hair in people with alopecia areata.

This article reviews the use of cyproterone acetate for conditions like prostate cancer and sexual disorders, highlighting its effects on libido but reporting no new specific trial results.

This study assessed the safety and efficacy of Romantaque lotion for unwanted hair growth and found statistically significant hair growth inhibition with no adverse effects in 30 volunteers after repeated applications over one year.

This study reported that Cacumen Platycladi extract significantly reduced hair loss and increased hair density in a 12-week clinical trial, suggesting it may be a safe and effective natural treatment.

This study found that after 24 weeks of DPCP treatment for alopecia areata, there was a significant increase in new capillaries and hair regrowth detectable by videocapillaroscopy.

The Paxbp1 gene is crucial for healthy hair follicles.

This study synthesized calcium citrate nanoparticles to improve the solubility and reduce the irritation of minoxidil solutions for treating androgenetic alopecia.

This study developed a new finasteride capsule with accurate dosage and good stability, showing potential as an effective oral preparation with a tentative two-year shelf life.

This study developed cilostazol-loaded formulations for nose-to-brain delivery, finding that these formulations improved cilostazol's bioavailability by enhancing solubility, absorption, and permeability, achieving nearly 100% drug release in vitro within 2 hours.

This study observed some differences in clinical outcomes when comparing CPA with spironolactone, flutamide, and finasteride, but no differences with other therapies, possibly due to small study size and non-standardized assessments; adverse effects could not be fully compared across treatments.

In this study, fibroblasts treated with the small molecule peficitinib were reprogrammed into dermal papilla cell-like cells capable of inducing hair growth, offering a new strategy for hair loss treatment.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

In this study, Pilopeptan® Intensive, a nutritional supplement containing hydrolyzed collagen, Group B vitamins, and zinc, was found to significantly improve hair parameters in telogen effluvium patients, with sustained benefits observed posttreatment, although mild side effects were reported by some participants.

Entadfi, a mix of finasteride and tadalafil, is used for BPH.

This study found that ALRN-6924, a clinical-stage dual inhibitor, can selectively protect human scalp hair follicles from paclitaxel-induced toxicity and damage by inducing transient cell cycle arrest in healthy cells without affecting cancer cells, potentially reducing chemotherapy-induced alopecia.

This study found that systemic mycophenolate mofetil and topical clobetasol were equally effective at reducing lichen planopilaris activity over six months, but satisfaction differed between the treatments.

This study reports a case of complete hair regrowth in lichen planopilaris after 12 weeks of treatment with ixekizumab, suggesting its potential as a targeted therapy.

This study found that Plerixafor, a CXCR4 antagonist, promotes melanogenesis in melanocytes by increasing MITF and tyrosinase expression and enhancing melanocyte migration, and it effectively restores pigmentation in a mouse depigmentation model without toxicity, highlighting its potential for treating pigmentary disorders.

The optimized Cinchonine gel effectively fights acne bacteria and is safe for twice-daily use.

This review discusses the role of PPAR-γ in the pathogenesis of primary cicatricial alopecia, including its involvement in lichen planopilaris and treatment trials using PPAR-agonists, and reports no new clinical results.

In this study, teicoplanin significantly improved hair regrowth and follicle size in mice with dihydrotestosterone-induced androgenetic alopecia, suggesting its potential as a treatment option for hair loss due to its ability to enhance cell proliferation and decrease androgen receptor protein levels.

This systematic review explored the potential of cetirizine, an anti-inflammatory antihistamine, as a complementary treatment for androgenetic alopecia, reporting that it might help prevent hair follicle miniaturization by reducing inflammation and modulating immune activity, without notable side effects.

In this study, topical 5% roxithromycin was effective in restoring hair growth in about half of individuals with androgenetic alopecia without causing adverse effects.

This study found that combined therapy with cetirizine and topical steroids stabilized inflammation in most patients with lichen planus pilaris, though one patient experienced cardiac arrhythmia.

This article discusses the introduction and market presence of the Italian hair product Kevis but presents no new clinical findings.